psilodex.org/m/terazosin · data v2026.10.02
Clinical data and state rules are separate facts. Both are shown; neither is a decision.
Due for review. This record was last reviewed on 2026-10-02, more than a year ago. Newer evidence or label changes may not be reflected yet.
Alpha-1 blocker that can cause marked postural hypotension and fainting, most often with the first doses or when restarted after a lapse. Adds to the lightheadedness on standing that can occur during a psilocybin session.
No provision names this medication or its class.
Colorado · checked 2026-09-30Rule check overdue · the rules may have changed sinceNo provision names this medication or its class.
Oregon · checked 2026-09-30Rule check overdue · the rules may have changed sinceNew Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.
New Mexico · checked 2026-10-02Rule check overdue · the rules may have changed sinceThis medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.